Sesen Bio, Inc. (SESN)

0.4250 +0.0357 (+9.17%) At close: 04:00PM EDT

Sesen Bio, Inc.

245 First Street
Suite 1800
Cambridge, MA 02142
United States
617 444 8550
https://sesenbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 35

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Thomas R. Cannell D.V.M.	Pres, CEO & Director	798.61k	N/A	1962
Ms. Monica Forbes	CFO & Treasurer	527.4k	N/A	1976
Dr. Glen C. MacDonald	Chief Technology Officer	512.27k	N/A	1951
Dr. Gregory L. Verdine Ph.D.	Co-Founder	N/A	N/A	1959
Ms. Elly Ryu	Corp. Controller & Principal Accounting Officer	N/A	N/A	1981
Ms. Erin Clark	VP of Corp. Strategy & Investor Relations	N/A	N/A	N/A
Mr. Mark R. Sullivan	Gen. Counsel & Corp. Sec.	N/A	N/A	1971
Mr. John Knighton	VP & Chief Compliance Officer	N/A	N/A	1978
Mr. Steve Barbera	VP of Market Access	N/A	N/A	N/A
Dr. David Brooks	Sr. VP of Clinical Devel.	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Sesen Bio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.